-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Pd9WFJDsiFnGKXzbkb8Yzio96d++1zsPBtrs1uj/LnAiKTjtuvWbofE8Q0KHfUCY XJK7OFASempkGemjOFyy4A== 0001144204-07-016392.txt : 20070402 0001144204-07-016392.hdr.sgml : 20070402 20070402154206 ACCESSION NUMBER: 0001144204-07-016392 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061230 FILED AS OF DATE: 20070402 DATE AS OF CHANGE: 20070402 EFFECTIVENESS DATE: 20070402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FAMILYMEDS GROUP, INC. CENTRAL INDEX KEY: 0000921878 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 341755390 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15445 FILM NUMBER: 07738632 BUSINESS ADDRESS: STREET 1: 312 FARMINGTON AVENUE CITY: FARMINGTON STATE: CT ZIP: 06032-1968 BUSINESS PHONE: 8606761222 MAIL ADDRESS: STREET 1: 312 FARMINGTON AVENUE CITY: FARMINGTON STATE: CT ZIP: 06032-1968 FORMER COMPANY: FORMER CONFORMED NAME: DRUGMAX INC DATE OF NAME CHANGE: 20011128 FORMER COMPANY: FORMER CONFORMED NAME: DRUGMAX COM INC DATE OF NAME CHANGE: 20000208 FORMER COMPANY: FORMER CONFORMED NAME: NUTRICEUTICALS COM CORP DATE OF NAME CHANGE: 19990629 NT 10-K 1 v070025_nt10k.htm Unassociated Document
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
    
 
 
 
Commission File Number: 1-15445
 



(Check One):
x Form 10-K
¨ Form 20-F
¨ Form 11-K
¨ Form 10-Q
¨ Form 10-D
 
¨ Form N-SAR
¨ Form N-CSR      
   
 
 
 
For Period Ended: December 30, 2006
 
 
¨ Transition Report on Form 10-K and Form 10-KSB
 
 
¨ Transition Report on Form 20-F
 
 
¨ Transition Report on Form 11-K
 
 
¨ Transition Report on Form 10-Q and Form 10-QSB
 
 
¨ Transition Report on Form N-SAR
 
 
 
 
For the Transition Period Ended: ________________.

Read Attached Instructions Before Preparing Form. Please Print or Type.
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
  

PART I — REGISTRANT INFORMATION
 
Familymeds Group, Inc.
Full Name of Registrant
 
 Former Name if Applicable
 
312 Farmington Avenue
 Address of Principal Executive Office (Street and Number)
 
Farmington, CT 06032
City, State and Zip Code
 




PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
 
 
 
(a)
 
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x
 
(b)
 
The subject annual report, semi-annual report, transition report on Form 10-K, Form 10-KSB, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, Form 10-QSB, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
 
 
(c)
 
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 

 
PART III — NARRATIVE
 
State below in reasonable detail the reasons why the Form 10-K, 10-KSB, 11-K, 20-F, 10-Q, 10-QSB, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed).
 
Familymeds Group, Inc. (the “Registrant”) has not finalized its consolidated financial statements for the year ended December 30, 2006 and its audit has yet to be completed. In part, the delays are a result of the Registrant’s board’s recent decision to adopt a Plan of Liquidation, pursuant to which the assets of the Registrant will be sold, as previously disclosed. The Plan of Liquidation and the sale of substantially all of the Registrant’s assets was approved by the Registrant’s shareholders. Management has been focused on these efforts, negotiating the sale contract and preparing, filing and mailing the proxy statement to its shareholders. The Registrant held a special meeting of its shareholders to approve the Plan of Liquidation and asset sale on March 30, 2007. The Registrant anticipates filing its Form 10-K within the grace period provided under Rule 12b-25.
 
Some of the statements contained in Part II, III and IV of this Form 12b-25 are forward-looking statements that are subject to risks and uncertainties, including, but not limited to, the Registrant’s ability to finalize its Form 10-K by the prescribed filing date. These risks could cause the Registrant’s actual results to differ from those expressed in any forward-looking statement made by, or on behalf of, the Registrant.
 
PART IV— OTHER INFORMATION
 
(1)
 
Name and telephone number of person to contact in regard to this notification

Allison Kiene
(860) 676-1222 ext. 117
(Name)
(Area Code)(Telephone Number)
 
(2)
 
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes ¨ No
 
(3)
 
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨Yes x No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.




2

Familymeds Group, Inc.
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: April 2, 2007
 
 
/s/ Edgardo A. Mercadante
 
 
 
By: Edgardo A. Mercadante
Title: Chief Executive Officer, President and Chairman of the Board
 
Instruction. The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
 
3
 -----END PRIVACY-ENHANCED MESSAGE-----